BR0014998A - ácido nucleico e polipeptìdio isolado, sonda de nucleotìdeos ou iniciador especìfico para um gene de abc1, métodos para amplificar uma região de um ácido nucleico, para detectar um ácido nucleico e um polipeptìdeo e para selecionar um composto ativo sobre o metabolismo do colesterol, um agonista, ou um antagonista de um polipeptìdeo de abc1, kits para amplificar e para detectar um ácido nucleico e um polipeptìdeo, vetor e célula hospedeira recombinante, anticorpo, composição farmacêutica, usos e um ácido nucleico, de um vetor e de célula hospedeira recombinante e de um polipeptìdeo, e, implante - Google Patents
ácido nucleico e polipeptìdio isolado, sonda de nucleotìdeos ou iniciador especìfico para um gene de abc1, métodos para amplificar uma região de um ácido nucleico, para detectar um ácido nucleico e um polipeptìdeo e para selecionar um composto ativo sobre o metabolismo do colesterol, um agonista, ou um antagonista de um polipeptìdeo de abc1, kits para amplificar e para detectar um ácido nucleico e um polipeptìdeo, vetor e célula hospedeira recombinante, anticorpo, composição farmacêutica, usos e um ácido nucleico, de um vetor e de célula hospedeira recombinante e de um polipeptìdeo, e, implanteInfo
- Publication number
- BR0014998A BR0014998A BR0014998-5A BR0014998A BR0014998A BR 0014998 A BR0014998 A BR 0014998A BR 0014998 A BR0014998 A BR 0014998A BR 0014998 A BR0014998 A BR 0014998A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- polypeptide
- abc1
- amplifying
- cell
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 10
- 102000039446 nucleic acids Human genes 0.000 title abstract 10
- 150000007523 nucleic acids Chemical class 0.000 title abstract 10
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 101150090313 abc1 gene Proteins 0.000 title abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000007943 implant Substances 0.000 title abstract 2
- 230000004060 metabolic process Effects 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000523 sample Substances 0.000 title 1
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 abstract 4
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 abstract 4
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- -1 ANTIBODY Substances 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 108020004635 Complementary DNA Proteins 0.000 abstract 1
- 108700024394 Exon Proteins 0.000 abstract 1
- 108091092195 Intron Proteins 0.000 abstract 1
- 208000001163 Tangier disease Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000001364 causal effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003999 initiator Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000004141 reverse cholesterol transport Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Abstract
"áCIDO NUCLEICO E POLIPEPTìDEO ISOLADO, SONDA DE NUCLEOTìDEOS OU INICIADOR ESPECìFICO PARA UM GENE DE ABC1, MéTODOS PARA AMPLIFICAR UMA REGIãO DE UM áCIDO NUCLEICO, PARA DETECTAR UM áCIDO NUCLEICO E UM POLIPEPTìDEO E PARA SELECIONAR UM COMPOSTO ATIVO SOBRE O METABOLISMO DO COLESTEROL, UM AGONISTA, OU UM ANTAGONISTA DE UM POLIPEPTìDEO DE ABC1, KITS PARA AMPLIFICAR E PARA DETECTAR UM áCIDO NUCLEICO E UM POLIPEPTìDEO, VETOR E CéLULA HOSPEDEIRA RECOMBINANTE, ANTICORPO, COMPOSIçãO FARMACêUTICA, USOS DE UM áCIDO NUCLEICO, DE UM VETOR E DE CéLULA HOSPEDEIRA RECOMBINANTE E DE UM POLIPEPTìDEO, E, IMPLANTE". A presente invenção refere-se a ácidos nucleicos que correspondem aos vários exons e íntrons do gene de ABC1, que é um gene causal para patologias ligadas a uma disfunção do metabolismo do colesterol induzindo doenças, como arteriosclerose, mais particularmente disrupção do transporte reverso do colesterol, e, mais particularmente, deficiências familiares de HDL (FHD), como a doença de Tangier. A presente invenção também se refere a cDNAs de ABC1 codificando a proteína ABC1 de comprimento pleno que é inédita. A invenção também se refere a meios para a detecção de polimorfismos em geral, e de mutações em particular, no gene de ABC1 ou na proteína correspondente produzida pela forma alélica do gene de ABC1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99402668A EP1096012A1 (en) | 1999-10-26 | 1999-10-26 | Nucleics acids of the human ABC1 gene and their therapeutic and diagnostic application |
| US18626000P | 2000-03-01 | 2000-03-01 | |
| PCT/EP2000/010886 WO2001030848A2 (en) | 1999-10-26 | 2000-10-26 | Nucleic acids of the human abc1 gene and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014998A true BR0014998A (pt) | 2003-06-17 |
Family
ID=8242152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014998-5A BR0014998A (pt) | 1999-10-26 | 2000-10-26 | ácido nucleico e polipeptìdio isolado, sonda de nucleotìdeos ou iniciador especìfico para um gene de abc1, métodos para amplificar uma região de um ácido nucleico, para detectar um ácido nucleico e um polipeptìdeo e para selecionar um composto ativo sobre o metabolismo do colesterol, um agonista, ou um antagonista de um polipeptìdeo de abc1, kits para amplificar e para detectar um ácido nucleico e um polipeptìdeo, vetor e célula hospedeira recombinante, anticorpo, composição farmacêutica, usos e um ácido nucleico, de um vetor e de célula hospedeira recombinante e de um polipeptìdeo, e, implante |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1096012A1 (pt) |
| JP (1) | JP2003523177A (pt) |
| AU (1) | AU1391901A (pt) |
| BR (1) | BR0014998A (pt) |
| CA (1) | CA2388950A1 (pt) |
| HU (1) | HUP0400492A3 (pt) |
| WO (1) | WO2001030848A2 (pt) |
| ZA (1) | ZA200203269B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821774B1 (en) | 1999-06-18 | 2004-11-23 | Cv Therapeutics, Inc. | Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1 |
| US6835563B1 (en) | 1999-06-18 | 2004-12-28 | Cv Therapeutics | Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1 |
| WO2001070810A2 (en) * | 2000-03-20 | 2001-09-27 | Bayer Aktiengesellschaft | Atp binding cassette transporter 1 (abc1) gene polymorphisms and uses thereof for the diagnosis and treatment of lipid disorders, cardiovascular diseases and inflammatory diseases |
| FR2815970A1 (fr) * | 2000-10-31 | 2002-05-03 | Aventis Pharma Sa | Sequences polymorphes du gene humain abca1, leurs utilisations, les methodes et kits de detection |
| CA2427436A1 (fr) * | 2000-10-31 | 2002-05-10 | Aventis Pharma S.A. | Sequences polymorphes du gene humain abca1, leurs utilisations, les methodes et kits de detection. |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| EP1828781A1 (en) * | 2004-12-11 | 2007-09-05 | Science and Technology Facilities Council | Assay for generation of a lipid profile using fluorescence measurement |
| CA2654608A1 (en) * | 2006-06-07 | 2007-12-13 | Reddy Us Therapeutics, Inc. | Compositions and methods to enhance reverse cholesterol transport |
| WO2021099573A1 (en) * | 2019-11-21 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml) |
-
1999
- 1999-10-26 EP EP99402668A patent/EP1096012A1/en not_active Withdrawn
-
2000
- 2000-10-26 BR BR0014998-5A patent/BR0014998A/pt not_active IP Right Cessation
- 2000-10-26 EP EP00975997A patent/EP1257651A2/en not_active Withdrawn
- 2000-10-26 HU HU0400492A patent/HUP0400492A3/hu unknown
- 2000-10-26 CA CA002388950A patent/CA2388950A1/en not_active Abandoned
- 2000-10-26 AU AU13919/01A patent/AU1391901A/en not_active Abandoned
- 2000-10-26 WO PCT/EP2000/010886 patent/WO2001030848A2/en not_active Application Discontinuation
- 2000-10-26 JP JP2001533845A patent/JP2003523177A/ja not_active Withdrawn
-
2002
- 2002-04-24 ZA ZA200203269A patent/ZA200203269B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003523177A (ja) | 2003-08-05 |
| WO2001030848A3 (en) | 2002-09-12 |
| EP1257651A2 (en) | 2002-11-20 |
| AU1391901A (en) | 2001-05-08 |
| ZA200203269B (en) | 2003-07-24 |
| EP1096012A1 (en) | 2001-05-02 |
| HUP0400492A3 (en) | 2006-01-30 |
| WO2001030848A2 (en) | 2001-05-03 |
| CA2388950A1 (en) | 2001-05-03 |
| HUP0400492A2 (hu) | 2004-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bogatkevich et al. | Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease | |
| Padeh et al. | Colchicine is a safe drug in children with familial Mediterranean fever | |
| Li et al. | Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-κB signaling in human arterial smooth muscle cells | |
| Stoller et al. | A review of α1-antitrypsin deficiency | |
| Edgerton et al. | IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice | |
| Amara et al. | Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis | |
| Desforges et al. | The SNAT4 isoform of the system A amino acid transporter is functional in human placental microvillous plasma membrane | |
| Li et al. | The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis | |
| Benchenane et al. | Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory | |
| JP2022521454A (ja) | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 | |
| Ledig et al. | BMP15 mutations in XX gonadal dysgenesis and premature ovarian failure | |
| Dimeloe et al. | Vitamin D (1, 25 (OH) 2D3) induces α-1-antitrypsin synthesis by CD4+ T cells, which is required for 1, 25 (OH) 2D3-driven IL-10 | |
| Balestra et al. | An engineered U1 small nuclear RNA rescues splicing‐defective coagulation F7 gene expression in mice | |
| He et al. | Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat/high-cholesterol diet and low-dose streptozotocin | |
| BR0014998A (pt) | ácido nucleico e polipeptìdio isolado, sonda de nucleotìdeos ou iniciador especìfico para um gene de abc1, métodos para amplificar uma região de um ácido nucleico, para detectar um ácido nucleico e um polipeptìdeo e para selecionar um composto ativo sobre o metabolismo do colesterol, um agonista, ou um antagonista de um polipeptìdeo de abc1, kits para amplificar e para detectar um ácido nucleico e um polipeptìdeo, vetor e célula hospedeira recombinante, anticorpo, composição farmacêutica, usos e um ácido nucleico, de um vetor e de célula hospedeira recombinante e de um polipeptìdeo, e, implante | |
| US20240066098A1 (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| Ahmed et al. | Granisetron and carvedilol can protect experimental rats againstadjuvant-induced arthritis | |
| Miller et al. | Vitamin B12 deficiency, tumor necrosis factor-α, and epidermal growth factor: a novel function for vitamin B12? | |
| Balakrishnan et al. | Salubrinal enhances eIF2α phosphorylation and improves fertility in a mouse model of classic galactosemia | |
| Doria et al. | Autoinflammatory diseases: how to put the fire inside the body out? | |
| Chen et al. | Evidence for a replication function of FFA-1, the Xenopus orthologue of Werner syndrome protein | |
| Rider | The heterogeneity of juvenile myositis | |
| US20130095127A1 (en) | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) | |
| Zhang et al. | Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines | |
| Doshi et al. | Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |